Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1

BACKGROUND AND OBJECTIVES: Neurofibromatosis type 1 (NF1)-associated cognitive impairments carry significant lifelong morbidity. The lack of targeted biologic treatments remains a significant unmet need. We examine changes in cognition in patients with NF1 in the first 48 weeks of mitogen-activated...

Descripción completa

Detalles Bibliográficos
Autores principales: Walsh, Karin S., Wolters, Pamela L., Widemann, Brigitte C., del Castillo, Allison, Sady, Maegan D., Inker, Tess, Roderick, Marie Claire, Martin, Staci, Toledo-Tamula, Mary Anne, Struemph, Kari, Paltin, Iris, Collier, Victoria, Mullin, Kathy, Fisher, Michael J., Packer, Roger J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351286/
https://www.ncbi.nlm.nih.gov/pubmed/34377779
http://dx.doi.org/10.1212/NXG.0000000000000616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351286/
https://www.ncbi.nlm.nih.gov/pubmed/34377779
http://dx.doi.org/10.1212/NXG.0000000000000616

Ejemplares similares